» Articles » PMID: 37563351

Delineation and Agreement of FET PET Biological Volumes in Glioblastoma: Results of the Nuclear Medicine Credentialing Program from the Prospective, Multi-centre Trial Evaluating FET PET In Glioblastoma (FIG) Study-TROG 18.06

Abstract

Purpose: The O-(2-[F]-fluoroethyl)-L-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Before participant recruitment, site nuclear medicine physicians (NMPs) underwent credentialing of FET PET delineation and image interpretation.

Methods: Sites were required to complete contouring and dynamic analysis by ≥ 2 NMPs on benchmarking cases (n = 6) assessing biological tumour volume (BTV) delineation (3 × FET1) and image interpretation (3 × FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR (TBR), dynamic analysis (time activity curve [TAC] type, time to peak), and qualitative assessment. Intraclass correlation coefficient (ICC) assessed volume agreement, coefficient of variation (CoV) compared maximum/mean TBR (TBR/TBR) across cases, and pairwise analysis assessed spatial (Dice similarity coefficient [DSC]) and boundary agreement (Hausdorff distance [HD], mean absolute surface distance [MASD]).

Results: Data was accrued from 21 NMPs (10 centres, n ≥ 2 each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows: BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV, TBR, and TBR were 21.53% (12.00-30.10%), 5.89% (5.01-6.68%), and 5.01% (3.37-6.34%), respectively. BTV agreement was moderate to excellent (ICC = 0.82; 95% CI, 0.63-0.97) with good spatial (DSC = 0.84 ± 0.09) and boundary (HD = 15.78 ± 8.30 mm; MASD = 1.47 ± 1.36 mm) agreement.

Conclusion: The FIG study credentialing program has increased expertise across study sites. TBR and TBR were robust, with considerable variability in BTV delineation and image interpretation observed.

Citing Articles

A Biopsy-Controlled Prospective Study of Contrast-Enhancing Diffuse Glioma Infiltration Based on FET-PET and FLAIR.

Harat M, Miechowicz I, Rakowska J, Zarebska I, Malkowski B Cancers (Basel). 2024; 16(7).

PMID: 38610944 PMC: 11010945. DOI: 10.3390/cancers16071265.


[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program.

Barry N, Koh E, Ebert M, Moore A, Francis R, Rowshanfarzad P Phys Imaging Radiat Oncol. 2024; 30:100568.

PMID: 38585372 PMC: 10998205. DOI: 10.1016/j.phro.2024.100568.


F-Fluoroethyl-L Tyrosine Positron Emission Tomography Radiomics in the Differentiation of Treatment-Related Changes from Disease Progression in Patients with Glioblastoma.

Manzarbeitia-Arroba B, Hodolic M, Pichler R, Osipova O, Soriano-Castrejon A, Garcia-Vicente A Cancers (Basel). 2024; 16(1).

PMID: 38201621 PMC: 10778283. DOI: 10.3390/cancers16010195.


PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.

Albert N, Galldiks N, Ellingson B, van den Bent M, Chang S, Cicone F Lancet Oncol. 2024; 25(1):e29-e41.

PMID: 38181810 PMC: 11787868. DOI: 10.1016/S1470-2045(23)00525-9.


Boosting the acceptance of F-FET PET for image-guided treatment planning with a multi-centric prospective trial.

Langen K, Galldiks N, Lohmann P, Mottaghy F Eur J Nucl Med Mol Imaging. 2023; 50(13):3817-3819.

PMID: 37682302 PMC: 10611633. DOI: 10.1007/s00259-023-06426-7.

References
1.
Suchorska B, Jansen N, Linn J, Kretzschmar H, Janssen H, Eigenbrod S . Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015; 84(7):710-9. DOI: 10.1212/WNL.0000000000001262. View

2.
Albert N, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim M . Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18(9):1199-208. PMC: 4999003. DOI: 10.1093/neuonc/now058. View

3.
Koo T, Li M . A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016; 15(2):155-63. PMC: 4913118. DOI: 10.1016/j.jcm.2016.02.012. View

4.
Overcast W, Davis K, Ho C, Hutchins G, Green M, Graner B . Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. Curr Oncol Rep. 2021; 23(3):34. PMC: 7892735. DOI: 10.1007/s11912-021-01020-2. View

5.
Kubben P, Postma A, Kessels A, Van Overbeeke J, van Santbrink H . Intraobserver and interobserver agreement in volumetric assessment of glioblastoma multiforme resection. Neurosurgery. 2010; 67(5):1329-34. DOI: 10.1227/NEU.0b013e3181efbb08. View